Ondine Biomedical Inc. Stock Analysis OBI.L

Ondine Biomedical, Inc. operates as a life sciences company that develops photodisinfection-based therapies to address drug-resistant infections. The firm specializes in light-activated antimicrobial therapies (photo disinfection) for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. The firm has a pipeline of investigational products, based on its proprietary photo disinfection technology, in various stages of development. The firm's nasal photo disinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave. In the United States, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is undergoing clinical trials for regulatory approval. Its products beyond nasal photo disinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, serious burns, chronic wounds, central line bloodstream infections and other indications.